skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Gadofosveset-enhanced magnetic resonance angiography

Review

(2565) Views  (593) Full article downloads

Authors: Mathias Goyen

Published Date March 2008 Volume 2008:4(1) Pages 1 - 9
DOI: http://dx.doi.org/10.2147/VHRM.S1968

Mathias Goyen

University Medical Center Hamburg- Eppendorf, Hamburg, Germany

Abstract: Gadofosveset (Vasovist®, Bayer Schering Pharma AG, Berlin/Germany) is the first intravascular contrast agent approved for use with magnetic resonance angiography in the European Union, Switzerland, Turkey, Canada, and Australia. Gadofosveset reversibly binds to albumin providing extended intravascular enhancement compared with existing extracellular magnetic resonance contrast agents. Prior to approval, gadofosveset underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials show that gadofosveset-enhanced magnetic resonance angiography (MRA) is safe and well tolerated in patients with vascular disease and effective for the detection of vascular stenosis and aneurysms gadofosveset has the potential to open new horizons in diagnostic MRA by increasing the spatial resolution and the robustness of MRA examinations and facilitating the examination of multiple vascular beds.

Keywords: gadofosveset, Vasovist®, magnetic resonance imaging, magnetic resonance contrast agent, magnetic resonance angiography (MRA)








Readers of this article also read:

Endothelial effects of antihypertensive treatment: focus on irbesartan
Kaposiform hemangioendothelioma with distant lymphangiomatosis without an association to Kasabach-Merritt-Syndrome in a female adult!
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
Coronary computed tomographic angiography (CCTA) in community hospitals: “current and emerging role”
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits
Corrigendum
Current state of cardiac rehabilitation in Germany: patient characteristics, risk factor management and control status, by education level
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University